Table 2.

Effects of comorbidities and medications on log-NLR.

	+	−	p-value
Male gender (M+,W-)	0.405 ± 0.214	0.385 ± 0.226	0.654
Comorbidity
Hypertension	0.417 ± 0.211	0.333 ± 0.234	0.102
Diabetes mellitus	0.453 ± 0.221	0.353 ± 0.208	0.024
Dyslipidemia	0.372 ± 0.201	0.420 ± 0.233	0.280
Heart failure	0.452 ± 0.177	0.384 ± 0.226	0.234
Angina pectoris	0.389 ± 0.179	0.399 ± 0.231	0.839
Old myocardial infarction	0.406 ± 0.222	0.394 ± 0.218	0.824
History of PCI	0.420 ± 0.194	0.391 ± 0.225	0.602
Cerebral infarction	0.548 ± 0.242	0.374 ± 0.207	0.007
Cerebral hemorrhage	0.564 ± 0.188	0.393 ± 0.218	0.276
Peripheral artery disease	0.536 ± 0.217	0.352 ± 0.200	<0.001
History of gastroduodenal ulcer	0.459 ± 0.234	0.392 ± 0.218	0.439
Reflux esophagitis	0.466 ± 0.179	0.390 ± 0.222	0.320
Medications
ARB	0.400 ± 0.194	0.394 ± 0.244	0.894
Diuretic agents	0.490 ± 0.211	0.351 ± 0.209	0.003
ACEI	0.531 ± 0.213	0.380 ± 0.214	0.030
Calcium channel blockers	0.436 ± 0.195	0.362 ± 0.234	0.095
β-blockers	0.389 ± 0.171	0.402 ± 0.245	0.770
Antiplatelet agents	0.426 ± 0.242	0.364 ± 0.190	0.166
Warfarin	0.426 ± 0.176	0.392 ± 0.225	0.605
PPI	0.415 ± 0.203	0.389 ± 0.226	0.584
H2-blockers	0.425 ± 0.241	0.392 ± 0.215	0.593
Statins	0.403 ± 0.201	0.394 ± 0.227	0.862
Uric acid-lowering agents	0.436 ± 0.249	0.394 ± 0.217	0.622
Oral hypoglycemic agents	0.420 ± 0.237	0.391 ± 0.215	0.603
Insulin	0.733 ± 0.094	0.386 ± 0.213	0.006

Data given as mean ± SD or n (%). Differences in continuous variables between two groups were assessed using unpaired Student’s t-test.

ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; H₂-blocker: histamine type 2 receptor blocker; log-NLR: log-transformed neutrophil/lymphocyte ratio; PCI: percutaneous coronary intervention; PPI: proton pump inhibitor.